Current or prior (within the last 30 days of the V-1 MMTT) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin.
10. Previous or current diagnosis of malignancy. 11. History of bone marrow transplantation, or autoimmune disease associated with
lymphopenia.
12. History or diagnoses of other autoimmune diseases with the exception of stable thyroid
or celiac disease.
13. History of significant cardiovascular disease. 14. Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella,
cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 30 days of V0.
15. Women of child-bearing potential who are unwilling to use a medically acceptable form
of contraception from 14 days prior to V0 until study Week 52.
16. Women who are pregnant, lactating, or planning on pregnancy during the study. 17. Current, diagnosed mental illness (e.g., severe depression), current diagnosed or
self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
18. Past or current medical problems or findings from physical examination or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.